Compare Moderna, Inc. (MRNA) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Xpeng Inc - ADR — how do they compare? Moderna, Inc. trades at $137.23 (market cap $56.02B), while Xpeng Inc - ADR trades at $10.63 (market cap $10.34B). The key difference: Moderna, Inc. is far larger — about 5.4× Xpeng Inc - ADR's market cap, and Moderna, Inc. is trading nearer its 52-week high, Xpeng Inc - ADR nearer its low. Which is the better fit depends on your goals.
| MRNA | XPEV | |
|---|---|---|
Market Cap | $56.02B | $10.34B |
Sector | Health | Consumer Cyclical |
52-Week High | $174.38 | $28.07 |
52-Week Low | $22.36 | $10.57 |
Enterprise Value | $52.17B | $12.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, amid mixed signals. The stock has seen volatility, with a 143% surge over the past month driven by positive cancer vaccine trial results (Fox Business, 2026-09-06), but faces headwinds from declining revenue and persistent net losses. Technical analysis shows a bullish overall signal, with support at $138 and resistance at $145, while fundamentals reveal a challenging profit margin of -142.58% for 2026.
The outlook hinges on pipeline successes, particularly in oncology, but high valuation ratios and competitive pressures pose risks. Analyst consensus is cautious, with a $90.08 price target, reflecting skepticism despite recent clinical milestones. Investors should weigh innovation potential against financial sustainability and market sentiment shifts.
XPEV trades at $10.93, down 0.18% for the day, with a bearish technical signal from moving averages. The company reported a net loss of $1.14B in 2025 despite revenue growth to $76.72B, and recent quarterly earnings missed expectations. Positive developments include a $900M robotics unit funding at a $6.3B valuation and new model launches aimed at boosting deliveries.
The outlook remains cautious due to persistent losses and competitive pressures, but analyst consensus is bullish with a $19 price target. Key risks include execution challenges in EV and robotics segments, while institutional interest and AI-driven initiatives offer potential upside if profitability improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
